2022 World Conference on Lung Cancer (ePosters)-EP08.02-082. Treatment Patterns and Outcomes of First-line Osimertinib-treated Advanced EGFR Mutated NSCLC Patients: A Real-world Study

EP08.02-082. Treatment Patterns and Outcomes of First-line Osimertinib-treated Advanced EGFR Mutated NSCLC Patients: A Real-world Study

Back to course

Pdf Summary

A real-world study was conducted to evaluate the treatment patterns and outcomes of patients with advanced non-small cell lung cancer (NSCLC) who were treated with first-line osimertinib, an EGFR tyrosine kinase inhibitor (TKI). The study aimed to explore survival outcomes, subsequent treatment lines, and sites of metastasis at disease progression in the real-world setting.<br /><br />The study included patients with stage IV NSCLC and confirmed EGFR mutations who were treated with first-line osimertinib at Princess Margaret Cancer Centre. Clinico-demographic data were collected from electronic records. The primary endpoint was progression-free survival (PFS), and secondary endpoints included subsequent treatment lines and sites of metastasis at disease progression.<br /><br />The results showed that patients in the real-world setting had comparable median PFS to the FLAURA trial, which demonstrated the efficacy of osimertinib. Disease progression was the main reason for permanent discontinuation of osimertinib, with 10% of patients discontinuing due to toxicity. Chemotherapy was the most common second-line treatment after disease progression, while a third of patients did not pursue second-line therapy.<br /><br />The study also highlighted the eventual failure of osimertinib due to progressive disease, which remains a major obstacle to long-term control of EGFR-mutated NSCLC. The survival outcomes and treatment patterns observed in this real-world study provide valuable insights into the management of patients with EGFR-mutated NSCLC receiving first-line osimertinib.<br /><br />In conclusion, this real-world study demonstrates the effectiveness of first-line osimertinib for the treatment of advanced EGFR-mutated NSCLC. However, disease progression and limited therapeutic options after osimertinib failure pose challenges in achieving long-term control. Further research and the development of novel treatment strategies are warranted to improve outcomes for patients with EGFR-mutated NSCLC.

Asset Subtitle

Jae Yun Lee

Meta Tag

Speaker Jae Yun Lee

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

real-world study

treatment patterns

outcomes

advanced non-small cell lung cancer

NSCLC

first-line osimertinib

EGFR tyrosine kinase inhibitor

survival outcomes

subsequent treatment lines

sites of metastasis